Adenocarcinoma
MONDO:0004970A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.
Also known as: adenocarcinoma, adenocarcinoma NOS (morphologic abnormality), adenocarcinoma, malignant, adenocarcinoma, no subtype (morphologic abnormality), adenocarcinomas, ADNOS
7753 clinical trials for this condition and its sub-types, 186 tagged with Adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Adenocarcinoma
-
Hepatocellular carcinoma 1,044 trials · 1,089 incl. sub-types
8 sub-types
- Hepatoblastoma 42 trials Sub-types →
- Pediatric hepatocellular carcinoma 36 trials
- Fibrolamellar hepatocellular carcinoma 15 trials Sub-types →
- Adult hepatocellular carcinoma 12 trials
- Aflatoxin-related hepatocellular carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Sclerosing hepatic carcinoma 0 trials
-
Pancreatic adenocarcinoma 496 trials · 929 incl. sub-types
5 sub-types
- Pancreatic ductal adenocarcinoma 553 trials Sub-types →
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma 1 trial
- Mucinous pancreas adenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
-
Renal cell carcinoma 611 trials · 710 incl. sub-types
11 sub-types
- Renal cell adenocarcinoma 98 trials · 250 incl. sub-types Sub-types →
- Nonpapillary renal cell carcinoma 156 trials · 246 incl. sub-types Sub-types →
- Adrenal cortex carcinoma 42 trials Sub-types →
- Collecting duct carcinoma 17 trials
- Kidney medullary carcinoma 10 trials · 13 incl. sub-types Sub-types →
- MIT family translocation renal cell carcinoma 6 trials Sub-types →
- Wolffian duct adenocarcinoma 2 trials
- Acquired cystic disease-associated renal cell carcinoma 0 trials
- Cystic renal cell carcinoma 0 trials
- Mucinous tubular and spindle renal cell carcinoma 0 trials
- Renal pelvis adenocarcinoma 0 trials
-
Tubular adenocarcinoma 0 trials · 558 incl. sub-types
4 sub-types
- Pancreatic ductal adenocarcinoma 553 trials Sub-types →
- Invasive tubular breast carcinoma 5 trials
- Gastric tubular adenocarcinoma 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Colorectal adenocarcinoma 246 trials · 546 incl. sub-types
5 sub-types
- Rectum adenocarcinoma 231 trials · 232 incl. sub-types Sub-types →
- Colon adenocarcinoma 90 trials · 121 incl. sub-types Sub-types →
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Colorectal serrated adenocarcinoma 1 trial
- Colorectal medullary carcinoma 0 trials Sub-types →
-
Gastroesophageal junction adenocarcinoma 507 trials
-
Gastric adenocarcinoma 449 trials · 481 incl. sub-types
9 sub-types
- Microinvasive gastric cancer 28 trials
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Gastric cardia adenocarcinoma 4 trials
- Signet ring cell gastric adenocarcinoma 2 trials
- CTNNA1-related diffuse gastric and lobular breast cancer syndrome 0 trials
- Gastric intestinal type adenocarcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Gastric tubular adenocarcinoma 0 trials
- Mucinous gastric adenocarcinoma 0 trials
-
Bile duct adenocarcinoma 17 trials · 418 incl. sub-types
1 sub-type
- Extrahepatic bile duct adenocarcinoma 2 trials · 408 incl. sub-types Sub-types →
-
Prostate adenocarcinoma 298 trials
2 sub-types
- Prostate adenoid cystic carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
-
Breast adenocarcinoma 36 trials · 279 incl. sub-types
13 sub-types
- Breast ductal adenocarcinoma 19 trials · 192 incl. sub-types Sub-types →
- Breast lobular carcinoma 13 trials · 34 incl. sub-types Sub-types →
- Inflammatory breast carcinoma 29 trials
- Lobular breast carcinoma in situ 27 trials
- Mixed lobular and ductal breast carcinoma 1 trial Sub-types →
- Adenoid cystic breast carcinoma 0 trials
- Breast malignant eccrine spiradenoma 0 trials
- Breast mucinous cystadenocarcinoma 0 trials
- Mammary Paget disease 0 trials Sub-types →
- Mucoepidermoid breast carcinoma 0 trials
- Oncocytic breast carcinoma 0 trials
- Sebaceous breast carcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
-
Serous adenocarcinoma 6 trials · 241 incl. sub-types
6 sub-types
- Ovarian serous adenocarcinoma 198 trials · 202 incl. sub-types Sub-types →
- Fallopian tube serous adenocarcinoma 71 trials
- Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types Sub-types →
- Endometrial serous adenocarcinoma 36 trials
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
-
Ovarian adenocarcinoma 12 trials · 230 incl. sub-types
7 sub-types
- Ovarian serous adenocarcinoma 198 trials · 202 incl. sub-types Sub-types →
- Ovarian endometrioid adenocarcinoma 77 trials Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Krukenberg carcinoma 1 trial
- Rete ovarii adenocarcinoma 0 trials
-
Clear cell adenocarcinoma 14 trials · 201 incl. sub-types
11 sub-types
- Clear cell renal carcinoma 140 trials · 142 incl. sub-types Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Urethra clear cell adenocarcinoma 1 trial
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Glycogen-rich clear cell breast carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
-
Esophageal adenocarcinoma 169 trials · 173 incl. sub-types
3 sub-types
- Barrett adenocarcinoma 6 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Mucoepidermoid esophageal carcinoma 0 trials
-
Adenocarcinoma in situ 10 trials · 170 incl. sub-types
3 sub-types
- Ductal breast carcinoma in situ 152 trials Sub-types →
- Lobular breast carcinoma in situ 27 trials
- Lung adenocarcinoma in situ 1 trial
-
Endometrioid adenocarcinoma 13 trials · 145 incl. sub-types
6 sub-types
- Ovarian endometrioid adenocarcinoma 77 trials Sub-types →
- Endometrial endometrioid adenocarcinoma 56 trials Sub-types →
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Stage I endometrioid carcinoma 16 trials
- Stage II endometrioid carcinoma 2 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
-
Endometrium adenocarcinoma 30 trials · 118 incl. sub-types
9 sub-types
- Ovarian endometrioid adenocarcinoma 77 trials Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Endometrial mixed adenocarcinoma 10 trials
- Endometrial mucinous adenocarcinoma 2 trials
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells 0 trials
- Mucin-rich endometrial endometrioid adenocarcinoma 0 trials
- Oxyphilic endometrial endometrioid adenocarcinoma 0 trials
- Secretory uterine corpus endometrioid adenocarcinoma 0 trials
- Villoglandular endometrial endometrioid adenocarcinoma 0 trials
-
Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types
3 sub-types
- Thyroid gland follicular carcinoma 20 trials · 77 incl. sub-types Sub-types →
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Thyroid gland mucoepidermoid carcinoma 0 trials
-
Lung adenocarcinoma 114 trials · 117 incl. sub-types
11 sub-types
- Minimally invasive lung adenocarcinoma 9 trials Sub-types →
- Lung adenocarcinoma in situ 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar lung adenocarcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Lung combined type small cell adenocarcinoma 0 trials
- Lung occult adenocarcinoma 0 trials
- Papillary lung adenocarcinoma 0 trials
- Solid adenocarcinoma with mucin production 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Gastroesophageal adenocarcinoma 93 trials
-
Papillary adenocarcinoma 2 trials · 92 incl. sub-types
11 sub-types
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Papillary renal cell carcinoma 25 trials · 27 incl. sub-types Sub-types →
- Ovarian serous surface papillary adenocarcinoma 2 trials
- Breast papillary carcinoma 1 trial Sub-types →
- Papillary eccrine carcinoma 1 trial Sub-types →
- Fallopian tube papillary adenocarcinoma 0 trials
- Gallbladder papillary neoplasm with an associated invasive carcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Papillary cystadenocarcinoma 0 trials Sub-types →
- Papillary lung adenocarcinoma 0 trials
- Papillary thymic adenocarcinoma 0 trials
-
Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types
5 sub-types
- Fallopian tube serous adenocarcinoma 71 trials
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Fallopian tube mucinous adenocarcinoma 9 trials
- Fallopian tube papillary adenocarcinoma 0 trials
-
Small intestine adenocarcinoma 18 trials · 60 incl. sub-types
2 sub-types
- Duodenal adenocarcinoma 9 trials · 44 incl. sub-types Sub-types →
- Jejunal adenocarcinoma 0 trials
-
Mucinous adenocarcinoma 18 trials · 57 incl. sub-types
17 sub-types
- Colon mucinous adenocarcinoma 2 trials · 21 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Fallopian tube mucinous adenocarcinoma 9 trials
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Endometrial mucinous adenocarcinoma 2 trials
- Mucoepidermoid carcinoma 2 trials Sub-types →
- Breast mucinous carcinoma 1 trial Sub-types →
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectum mucinous adenocarcinoma 1 trial Sub-types →
- Acinar prostate mucinous adenocarcinoma 0 trials
- Colloid carcinoma of the pancreas 0 trials
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Gallbladder mucinous adenocarcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Mucinous gastric adenocarcinoma 0 trials
- Mucinous pancreas adenocarcinoma 0 trials
- Salivary gland mucinous adenocarcinoma 0 trials
-
Adenoid cystic carcinoma 46 trials · 47 incl. sub-types
17 sub-types
- Paranasal sinus adenoid cystic carcinoma 5 trials Sub-types →
- Salivary gland adenoid cystic carcinoma 3 trials Sub-types →
- Bartholin gland adenoid cystic carcinoma 0 trials
- Adenoid cystic breast carcinoma 0 trials
- Adenoid cystic carcinoma of oropharynx 0 trials
- Adenoid cystic carcinoma of the corpus uteri 0 trials
- Cervical adenoid cystic carcinoma 0 trials
- Cutaneous adenocystic carcinoma 0 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Lacrimal gland adenoid cystic carcinoma 0 trials
- Laryngeal adenoid cystic carcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lymph node adenoid cystic carcinoma 0 trials
- Pharyngeal adenoid cystic carcinoma 0 trials
- Prostate adenoid cystic carcinoma 0 trials
- Tracheal adenoid cystic carcinoma 0 trials
- Vaginal adenoid cystic carcinoma 0 trials
-
Cervical adenocarcinoma 27 trials · 34 incl. sub-types
10 sub-types
- Cervical adenosquamous carcinoma 16 trials Sub-types →
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Endocervical adenocarcinoma 3 trials
- Wolffian duct adenocarcinoma 2 trials
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Cervical adenoid cystic carcinoma 0 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
- Early invasive cervical adenocarcinoma 0 trials
- Uterine ligament adenocarcinoma 0 trials Sub-types →
-
Acinar cell carcinoma 4 trials · 15 incl. sub-types
5 sub-types
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Acinic cell breast carcinoma 0 trials
- Parotid gland acinic cell carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
- Salivary gland acinic cell carcinoma 0 trials
-
Signet ring cell carcinoma 4 trials · 11 incl. sub-types
11 sub-types
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Signet ring cell gastric adenocarcinoma 2 trials
- Krukenberg carcinoma 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar prostate adenocarcinoma, signet ring variant 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Gallbladder signet ring cell adenocarcinoma 0 trials
- Pancreatic signet ring cell adenocarcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
- Signet ring cell variant cervical mucinous adenocarcinoma 0 trials
-
Gallbladder adenocarcinoma 9 trials
4 sub-types
-
Paget disease 2 trials · 9 incl. sub-types
5 sub-types
- Extramammary Paget disease 7 trials Sub-types →
- Cutaneous Paget disease 0 trials · 1 incl. sub-types Sub-types →
- Mammary Paget disease 0 trials Sub-types →
- Osteosarcoma arising in bone Paget disease 0 trials
- Scrotum Paget disease 0 trials
-
Bladder adenocarcinoma 5 trials · 8 incl. sub-types
7 sub-types
- Bladder urachal adenocarcinoma 5 trials
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Bladder mixed adenocarcinoma 1 trial
- Bladder colloid adenocarcinoma 0 trials
- Bladder colonic type adenocarcinoma 0 trials
- Bladder hepatoid adenocarcinoma 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
-
Vaginal adenocarcinoma 7 trials
1 sub-type
- Vaginal adenoid cystic carcinoma 0 trials
-
Diffuse type adenocarcinoma 1 trial · 6 incl. sub-types
1 sub-type
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
-
Cystadenocarcinoma 0 trials · 6 incl. sub-types
6 sub-types
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Biliary cystadenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
- Papillary cystadenocarcinoma 0 trials Sub-types →
-
Vulvar adenocarcinoma 3 trials · 5 incl. sub-types
7 sub-types
- Vulval Paget disease 2 trials
- Bartholin gland adenocarcinoma 0 trials Sub-types →
- Adenocarcinoma of skene gland origin 0 trials
- Vulvar apocrine adenocarcinoma 0 trials
- Vulvar clear cell hidradenocarcinoma 0 trials
- Vulvar eccrine adenocarcinoma 0 trials Sub-types →
- Vulvar sebaceous carcinoma 0 trials
-
Parathyroid gland carcinoma 4 trials
-
Pituitary adenocarcinoma 3 trials
3 sub-types
-
Sebaceous adenocarcinoma 2 trials · 3 incl. sub-types
3 sub-types
- Ocular sebaceous carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Sebaceous breast carcinoma 0 trials
- Vulvar sebaceous carcinoma 0 trials
-
Hepatoid adenocarcinoma 2 trials
1 sub-type
- Bladder hepatoid adenocarcinoma 0 trials
-
Mesonephric adenocarcinoma 2 trials
1 sub-type
- Wolffian duct adenocarcinoma 2 trials
-
Sweat gland carcinoma 1 trial · 2 incl. sub-types
4 sub-types
- Apocrine adenocarcinoma 2 trials Sub-types →
- Eccrine carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Cutaneous adenocystic carcinoma 0 trials
-
Urethra adenocarcinoma 1 trial · 2 incl. sub-types
1 sub-type
-
Micropapillary serous carcinoma 1 trial
-
Nasal cavity adenocarcinoma 1 trial
-
Seminal vesicle adenocarcinoma 1 trial
-
Trabecular adenocarcinoma 1 trial
-
Ureter adenocarcinoma 1 trial
-
Adenoacanthoma 0 trials
-
Epididymal adenocarcinoma 0 trials
-
Ethmoid sinus adenocarcinoma 0 trials
-
Granular cell carcinoma 0 trials
-
Intestinal type adenocarcinoma 0 trials
2 sub-types
-
Lacrimal gland adenocarcinoma 0 trials
2 sub-types
-
Maxillary sinus adenocarcinoma 0 trials
-
Middle ear adenocarcinoma 0 trials
-
Minor salivary gland adenocarcinoma 0 trials
1 sub-type
-
Rete testis adenocarcinoma 0 trials
-
Scirrhous adenocarcinoma 0 trials
-
Submandibular gland adenocarcinoma 0 trials
-
Thymus gland adenocarcinoma 0 trials
2 sub-types
- Papillary thymic adenocarcinoma 0 trials
- Thymic mucoepidermoid carcinoma 0 trials
-
Villous adenocarcinoma 0 trials
2 sub-types
Most studied deeper sub-types
-
New antibody GNR-051 tested for safety in Hard-to-Treat cancers
Disease control CompletedResearchers are testing an experimental immunotherapy called GNR-051 in adults with advanced lung cancer, kidney cancer, or melanoma that has returned or not responded to other treatments. The Phase 1 trial aims to find the highest dose people can tolerate and to track side effec…
Phase 1 • Sponsor: AO GENERIUM • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can High-Dose vitamin c boost chemo against pancreatic cancer?
Disease control CompletedThis phase II trial tests whether adding high-dose vitamin C (ascorbate) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with metastatic pancreatic cancer live longer. About 40 participants are randomly assigned to receive either standard chemo alone or …
Phase 2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Robot or scalpel? european trial tests less invasive pancreatic cancer surgery
Disease control CompletedThis trial compares two types of surgery for pancreatic cancer in the body or tail of the pancreas: minimally invasive (laparoscopic or robot-assisted) versus traditional open surgery. The goal is to see if the less invasive approach can remove the tumor just as completely. Adult…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to outperform chemo in Tough-to-Treat stomach cancer
Disease control CompletedThis phase 3 trial tested whether a combination of two drugs, regorafenib and nivolumab, helps people with advanced gastro-oesophageal cancer live longer than standard chemotherapy. The study included 462 adults whose cancer had stopped responding to prior treatments. The goal wa…
Phase 3 • Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Tailored immunotherapy cocktail shows promise for tough stomach cancer
Disease control CompletedThis phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while other…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Prostate cancer radiation cut to just 5 sessions in new trial
Disease control CompletedThis phase I trial tested a new type of radiation therapy for low- and intermediate-risk prostate cancer that delivers a higher dose each day, completing treatment in just 5 sessions over 2 weeks instead of the usual 45-48. The study enrolled 120 participants to check the safety …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cocktail of chemo drugs shows promise for tough pancreatic cancer
Disease control CompletedThis study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Rectal cancer patients may avoid surgery with new Chemo-Radiation combo
Disease control CompletedThis study tested a treatment plan for locally advanced rectal cancer that uses a short course of radiation followed by chemotherapy, aiming to avoid surgery. 39 patients were enrolled. The goal was to see if the cancer could be completely controlled without an operation, using a…
Phase 2 • Sponsor: Servicio de Salud Metropolitano Sur Oriente • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cocktail of drugs shows promise for tough pancreatic cancer
Disease control CompletedThis study tested a combination of four drugs (tadalafil, pembrolizumab, ipilimumab, and CRS-207) in 17 people with advanced pancreatic cancer that had worsened after at least one round of chemotherapy. The goal was to see if the combination was safe and could shrink tumors. The …
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Lung cancer trial matches drugs to genes: a step toward personalized treatment
Disease control CompletedThis trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…
Phase 2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising drug combo targets Hard-to-Treat salivary cancer
Disease control CompletedThis phase 2 trial tested darolutamide, a drug that blocks male hormones, in 57 people with a rare type of salivary gland cancer that has male hormone receptors. Some patients received darolutamide alone, while others also got goserelin to lower hormone levels. The goal was to se…
Phase 2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo shows promise for stomach cancer patients with hidden HER2 signal
Disease control CompletedThis phase II study tested whether adding trastuzumab (a targeted therapy) to standard chemotherapy could help people with advanced stomach or gastroesophageal junction cancer. Unlike typical patients, these participants had tumors that tested negative for HER2 in tissue but posi…
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo tackles tough pancreatic cancer
Disease control CompletedThis study tested an experimental immunotherapy called indoximod added to standard chemotherapy (gemcitabine and nab-paclitaxel) in 157 people with metastatic pancreatic cancer. The goal was to find a safe dose and see if the combination helps people live longer. The trial has co…
Phase 1/2 • Sponsor: NewLink Genetics Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New clip could make robotic cancer surgery safer
Disease control CompletedThis study tested a new surgical clip called VasoClip, designed to hold blood vessels closed more securely during robotic surgery for prostate, kidney, or bladder cancer. Forty patients were randomly assigned to receive either the new clip or a standard clip. The goal was to see …
Phase 3 • Sponsor: Incheon St.Mary's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can adding radiation before surgery help stomach cancer patients live longer?
Disease control CompletedThis study tested whether adding radiation to chemotherapy before surgery improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 204 adults with operable tumors received either chemotherapy alone or chemotherapy plus radiation before…
Phase 3 • Sponsor: Shanghai Cancer Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy combo shows promise for inoperable esophageal cancer
Disease control CompletedThis Phase 2 trial tested whether adding the immunotherapy drug durvalumab to standard chemoradiation (FOLFOX and radiation) helps patients with unresectable esophageal cancer. 112 patients were randomly assigned to receive either chemoradiation alone or chemoradiation plus durva…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo tackles tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested two drugs, cabozantinib and pembrolizumab, in 21 people with metastatic pancreatic cancer that had worsened after standard treatment. The goal was to see if the combination could slow cancer growth. The study is complete, and results may help guide futur…
Phase 2 • Sponsor: Joseph Kim • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo shows promise for Tough-to-Treat bile duct cancer
Disease control CompletedThis phase 2 trial tested a new chemotherapy combination (Nal-IRI with 5-FU and leucovorin) against a standard treatment (gemcitabine plus cisplatin) in 93 people with advanced biliary tract cancer that could not be removed by surgery. The study aimed to see which approach better…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy shows promise for Hard-to-Treat cervical cancer
Disease control CompletedThis phase 2 study tested a combination of the immunotherapy drug cemiplimab and an HPV16-targeting vaccine (ISA101b) in 113 adults with recurrent or metastatic HPV16-positive cervical cancer that had progressed after first-line chemotherapy. The goal was to see if the combinatio…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 15:18 UTC
-
New PET scan agent could outshine MRI for prostate cancer detection
Diagnosis CompletedThis study is testing a new radioactive tracer called 68Ga-P16-093 for PET scans to see how well it finds prostate cancer tumors compared to standard MRI scans. About 50 people with newly diagnosed, untreated prostate cancer will receive both scans before their prostate removal s…
Phase 2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
Blood test aims to catch lung cancer earlier in smokers
Diagnosis CompletedThis study tested whether giving doctors access to a blood test called FirstLook increases lung cancer screening rates among people at high risk. The test looks for DNA fragments in the blood that may signal lung cancer. Researchers compared screening rates in practices that coul…
Sponsor: Delfi Diagnostics Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
New surgical 'HOOD' technique may help men regain bladder control faster after prostate cancer surgery
Symptom relief CompletedThis study looked at 200 men with early-stage prostate cancer who had robotic surgery to remove the prostate. It compared two surgical methods—the standard approach and a newer 'HOOD' technique—to see which one helps men regain bladder control sooner after surgery. The goal is to…
Sponsor: Araz Musaev • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
PET scan spots chemo success early in breast cancer
Knowledge-focused CompletedThis study looked at whether a special PET scan (FDG-PET) can detect early whether breast cancer is responding to chemotherapy. 63 women with breast cancer had a PET scan before and after their first chemo cycle. The goal was to see if the scan could tell responders from non-resp…
Phase 4 • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could a simple biopsy replace major surgery for multifocal breast cancer?
Knowledge-focused CompletedThis completed Phase 2 trial looked at whether the sentinel lymph node technique—a less invasive way to check if cancer has spread—works for women with multifocal breast cancer (more than one tumor in the same breast). 216 women with early-stage, node-negative multifocal breast c…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
PET scans may steer cancer therapy in real time
Knowledge-focused CompletedThis trial tests whether an early PET scan can help doctors choose the right treatment for people with locally advanced oesophago-gastric cancer. Patients receive one round of standard chemotherapy, then a second PET scan. If the tumor shows a strong response, they continue chemo…
Phase 2 • Sponsor: Masaryk Memorial Cancer Institute • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
What drives eyelid cancer in eastern morocco? a new study digs into the data
Knowledge-focused CompletedThis study reviews the medical records of 20 people treated for eyelid carcinomas at a hospital in eastern Morocco. Researchers are examining patient characteristics, tumor types, and surgical approaches to better understand how these cancers present and are managed in this regio…
Sponsor: Mohammed VI University Hospital • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New model could spare prostate cancer patients unnecessary surgery
Knowledge-focused CompletedThis study aimed to improve how doctors predict whether prostate cancer has spread to nearby lymph nodes. Researchers combined patient information, MRI scans, and genetic data from 367 men who had their prostate removed. The goal was to create a more accurate tool to help decide …
Sponsor: Francesco Montorsi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
AI vs. jargon: can robots make cancer info easier to read?
Knowledge-focused CompletedThis study tested whether an AI tool can help health providers write medical summaries that are easier for patients to understand. 120 providers were split into two groups: one used the AI tool, the other did not. The goal was to see if AI could improve readability and save time,…
Phase 2 • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Fiber-Fed mice show promise against prostate cancer
Knowledge-focused CompletedThis completed study from the University of Aberdeen looked at how dietary fiber supplements might influence prostate cancer. Researchers gave mice different fibers (inulin, pectin, hemp hull) along with stool samples from healthy men over 60. They then measured changes in gut ba…
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New biopsy needle tested in 183 patients
Knowledge-focused CompletedThis study tested the EchoTip AcuCore, a needle used during endoscopic ultrasound to collect tissue samples from the pancreas, liver, and other organs. 183 adults with conditions like cancer or chronic pancreatitis took part. The main goal was to see if the needle could get a goo…
Sponsor: Cook Research Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Does waiting longer for surgery after chemoradiation improve esophageal cancer outcomes?
Knowledge-focused CompletedThis study looked at whether waiting 10-12 weeks instead of the usual 4-6 weeks after chemoradiation before surgery helps patients with esophageal or gastric cardia cancer. 202 participants were randomly assigned to one of the two timing groups. The goal was to see if a longer de…
Sponsor: Karolinska University Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:40 UTC